Could Sars-Cov2 affect MS progression?

Di Stadio, Arianna; Romani, Luigina; Bernitsas, Evanthia

Di Stadio, Arianna; Romani, Luigina; Bernitsas, Evanthia.

Di Stadio A; Otolaryngology Department, University of Perugia, Perugia, Italy; Neuroinflammation Lab, Queen Square UCL Neurology, London, UK. Electronic address: Arianna.distadio@unipg.it.
Romani L; Department of Experimental Medicine, University of Perugia, Perugia, Italy.
Bernitsas E; Multiple Sclerosis Center, Wayne State University, Detroit (MI), USA.

Mult Scler Relat Disord ; 46: 102540, 2020 Nov.

Article in English | MEDLINE | ID: covidwho-803007

ABSTRACT

ABSTRACT

A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection.

Subject(s)

COVID-19/virology; Inflammasomes/metabolism; Multiple Sclerosis/complications; SARS-CoV-2/pathogenicity; COVID-19/complications; COVID-19/metabolism; Disease Progression; Humans; Interleukin-1beta/metabolism; Interleukin-1beta/pharmacology; Multiple Sclerosis/virology

Keywords

COVID-19; Inflammasomes; Long-term sequela; Microglia; Sars-CoV2, Multiple sclerosis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammasomes / SARS-CoV-2 / COVID-19 / Multiple Sclerosis Topics: Long Covid Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google